pharmacologic agents for treatment of Parkinson's disease
Jump to navigation
Jump to search
Adverse effects
- withholding Parkinson agents for surgery (Sinemet &/or dopaminergic receptor agonists) may result in parkinsonism-hyperpyrexia syndrome
Notes
- simvastatin useless as disease-modifying Parkinsonian agent[4]
More general terms
More specific terms
- amantadine; adamantamine (Symmetrel, Gocovri)
- benserazide (Serazide)
- benztropine <mesylate> (Cogentin)
- biperiden (Akineton)
- bromocriptine (Parlodel, Cycloset)
- carbidopa (Lodosyn)
- combination therapy for Parkinson's disease
- entacapone (Comtan)
- L-deprenyl (Selegiline, Eldepryl, Emsam, Zelapar)
- lazabemide (Tempium, Ro-19-6327)
- levodopa; L-3-hydroxytyrosine; L-3,4-dihydroxyphenylalanine; L-dopa (Dopar, Larodopa, Inbrija)
- opicapone (ONGENTYS)
- pergolide (Permax, pergolidum)
- piribedil (Trivastal)
- pramipexole (Mirapex)
- procyclidine (Kemadrin)
- rasagiline (Azilect)
- ropinirole (Requip, Requip-XL)
- rotigotine (Neupro)
- tolcapone (Tasmar)
- trihexyphenidyl (Artane, Trihexy)
References
- ↑ Prescriber's Letter 18(9): 2011 CHART: Comparison of Parkinson's Disease Drugs CHART: Parkinson's Disease Therapy Algorithm Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270920&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 3.0 3.1 Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18712508
- ↑ 4.0 4.1 Stevens KN, Creanor S, Jeffery A et al Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease. A Randomized Clinical Trial. JAMA Neurol. Published online October 31, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36315128 https://jamanetwork.com/journals/jamaneurology/fullarticle/2797508